Health Care Related Organization – Page 10

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

2 months ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

2 months ago talkbio0Tagged Amlitelimab, Asthma, Immunology, Kymab, sanofi

Asthma, Amlitelimab, Kymab, sanofi, Immunology

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

2 months ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

J&J brushes off tariff headwinds with raised forecast, oncology surge

2 months ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Sanofi backs $90M financing for I&I biologic developer

2 months ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

2 months ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay

2 months ago talkbio0Tagged alternatives, Clinical Trials, gene therapy, Hemgenix, HYMPAVZI, Pfizer, SMPX gene

Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

2 months ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 months ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Pharma stocks swerve as Trump hits pause on most tariffs

2 months ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses